Vanda Pharmaceuticals (VNDA)

$5.43 +0.27 (5.23%)
Market Cap 304.90M
Revenue (ttm) 198.77M
Net Income (ttm) -18.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.51%
Debt to Equity Ratio 0.00
Volume 862,400
Avg Vol 473,744
Day's Range N/A - N/A
Shares Out 59.09M
Stochastic %K 92%
Beta 0.74
Analysts Sell
Price Target $12.67

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 734 3400
Fax: 202 296 1450
Address:
2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States
Srjs93
Srjs93 Oct. 4 at 7:59 PM
$VNDA tons of ads this weekend. Thoughts?
0 · Reply
johnny6nine
johnny6nine Oct. 4 at 6:40 PM
$VNDA anyone got the skinny here? advertising behind home plate at the brewers game.. go crew!
0 · Reply
Trendrebel
Trendrebel Oct. 4 at 5:35 AM
$VNDA This chart here is VERY interesting ( if you are long or short ). These are the trendlines. HUGE resistance at the closing point from friday. If you look at the Ext. Fibonacci below ( 50% ). All lines come together. So the big question now is - is the Inversed SHS break of neckline a stronger signal, than the trendlines and Fibo 50% ??? If yes, next move will be ballistic. If no, we will go back and test the neckline at 5.11.
1 · Reply
Trendrebel
Trendrebel Oct. 4 at 5:15 AM
$VNDA This chart is the daily Extended Fibonacci, where we can see potential stops / reversals. This chart indicates short term expected movements. Like the weekly chart - it tells us, that 5.95 is the target ( Fibonacci 61,8% ). BUT we might test 50%, which have caused some problems earlier. If we cut through 50%, it should be a long green candle. We might be a little overbought ( RSI 71 ). But these - blown off top days - it´s not a warning signal.
0 · Reply
Trendrebel
Trendrebel Oct. 4 at 4:52 AM
$VNDA Dear friends... This is the weekly chart - and most reliant. We see that, our Inversed SHS have played perfectly out. We broke the neckline ( long horizontal blue line ). We landed perfectly on the Fibonacci 38,2%, but this line is more an indicator, than a real resistance. Important levels on Fibonacci is typical 23, 50 & 61 - and of course 0 & 100% * We should have no real resistance before 5.95 ( Fibonacci 23,8% ). * Fibonacci 100% is 6.76. If we go there, we will also test the weekly resistance at 7.01 ( purple line ). I give no buy/sell advice. But this chart is a dream to any swingtrader. Any green opening monday, should be a buying opportunity ( add to winner ). There is a 9% clear highway.
0 · Reply
HorizonBull
HorizonBull Oct. 4 at 3:11 AM
$VNDA Undervalued
0 · Reply
datapoint1728
datapoint1728 Oct. 3 at 10:00 PM
$VNDA anxiously waiting for the FDA result of November review.
0 · Reply
Trendrebel
Trendrebel Oct. 3 at 9:09 PM
$VNDA Even that we stopped at Fibo 38,2%, we will go non-stop to 5,95 next week. I will post chart later this weekend.
1 · Reply
Starlord10
Starlord10 Oct. 3 at 7:25 PM
$VNDA
0 · Reply
pablo4
pablo4 Oct. 3 at 7:15 PM
$VNDA we might push on to 6 before consolidating.....RSI is hot at over 70....but XBI's RSI is a bit higher....meaning whole sector is cooking (getting overbought). jmo
0 · Reply
Latest News on VNDA
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Oct 1, 2025, 5:02 PM EDT - 3 days ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Sep 25, 2025, 8:00 AM EDT - 9 days ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Aug 29, 2025, 3:21 PM EDT - 5 weeks ago

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 5:23 PM EDT - 5 weeks ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 28, 2025, 7:00 AM EDT - 5 weeks ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 21, 2025, 4:40 PM EDT - 6 weeks ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Aug 18, 2025, 7:00 AM EDT - 6 weeks ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:45 PM EDT - 2 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 2 months ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jul 23, 2025, 4:45 PM EDT - 2 months ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Jun 10, 2025, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 27, 2025, 9:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 16, 2025, 5:30 PM EDT - 5 months ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:55 PM EDT - 5 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 4:01 PM EDT - 5 months ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 5, 2025, 8:00 AM EDT - 5 months ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

May 2, 2025, 8:46 AM EDT - 5 months ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Apr 23, 2025, 3:52 PM EDT - 5 months ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Apr 7, 2025, 8:00 AM EDT - 6 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Feb 24, 2025, 7:00 AM EST - 7 months ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 10:29 PM EST - 8 months ago

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:01 PM EST - 8 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Feb 5, 2025, 4:30 PM EST - 8 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Jan 27, 2025, 7:00 AM EST - 8 months ago

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Jan 8, 2025, 4:17 PM EST - 9 months ago

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Dec 20, 2024, 1:26 PM EST - 10 months ago

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Dec 20, 2024, 9:13 AM EST - 10 months ago

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Dec 16, 2024, 9:29 PM EST - 10 months ago

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Nov 12, 2024, 4:58 PM EST - 11 months ago

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:20 PM EST - 11 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:02 PM EST - 11 months ago

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Nov 1, 2024, 2:05 PM EDT - 1 year ago

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Oct 14, 2024, 10:56 AM EDT - 1 year ago

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Oct 14, 2024, 10:37 AM EDT - 1 year ago

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

Oct 14, 2024, 8:19 AM EDT - 1 year ago

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

Sep 19, 2024, 3:17 PM EDT - 1 year ago

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies

Sep 19, 2024, 10:33 AM EDT - 1 year ago

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies

U.S. FDA declines to approve Vanda's stomach paralysis drug

Sep 19, 2024, 7:57 AM EDT - 1 year ago

U.S. FDA declines to approve Vanda's stomach paralysis drug

Srjs93
Srjs93 Oct. 4 at 7:59 PM
$VNDA tons of ads this weekend. Thoughts?
0 · Reply
johnny6nine
johnny6nine Oct. 4 at 6:40 PM
$VNDA anyone got the skinny here? advertising behind home plate at the brewers game.. go crew!
0 · Reply
Trendrebel
Trendrebel Oct. 4 at 5:35 AM
$VNDA This chart here is VERY interesting ( if you are long or short ). These are the trendlines. HUGE resistance at the closing point from friday. If you look at the Ext. Fibonacci below ( 50% ). All lines come together. So the big question now is - is the Inversed SHS break of neckline a stronger signal, than the trendlines and Fibo 50% ??? If yes, next move will be ballistic. If no, we will go back and test the neckline at 5.11.
1 · Reply
Trendrebel
Trendrebel Oct. 4 at 5:15 AM
$VNDA This chart is the daily Extended Fibonacci, where we can see potential stops / reversals. This chart indicates short term expected movements. Like the weekly chart - it tells us, that 5.95 is the target ( Fibonacci 61,8% ). BUT we might test 50%, which have caused some problems earlier. If we cut through 50%, it should be a long green candle. We might be a little overbought ( RSI 71 ). But these - blown off top days - it´s not a warning signal.
0 · Reply
Trendrebel
Trendrebel Oct. 4 at 4:52 AM
$VNDA Dear friends... This is the weekly chart - and most reliant. We see that, our Inversed SHS have played perfectly out. We broke the neckline ( long horizontal blue line ). We landed perfectly on the Fibonacci 38,2%, but this line is more an indicator, than a real resistance. Important levels on Fibonacci is typical 23, 50 & 61 - and of course 0 & 100% * We should have no real resistance before 5.95 ( Fibonacci 23,8% ). * Fibonacci 100% is 6.76. If we go there, we will also test the weekly resistance at 7.01 ( purple line ). I give no buy/sell advice. But this chart is a dream to any swingtrader. Any green opening monday, should be a buying opportunity ( add to winner ). There is a 9% clear highway.
0 · Reply
HorizonBull
HorizonBull Oct. 4 at 3:11 AM
$VNDA Undervalued
0 · Reply
datapoint1728
datapoint1728 Oct. 3 at 10:00 PM
$VNDA anxiously waiting for the FDA result of November review.
0 · Reply
Trendrebel
Trendrebel Oct. 3 at 9:09 PM
$VNDA Even that we stopped at Fibo 38,2%, we will go non-stop to 5,95 next week. I will post chart later this weekend.
1 · Reply
Starlord10
Starlord10 Oct. 3 at 7:25 PM
$VNDA
0 · Reply
pablo4
pablo4 Oct. 3 at 7:15 PM
$VNDA we might push on to 6 before consolidating.....RSI is hot at over 70....but XBI's RSI is a bit higher....meaning whole sector is cooking (getting overbought). jmo
0 · Reply
blankstocker
blankstocker Oct. 3 at 7:09 PM
$VNDA Nice. All of my shares here are now long so great time to take off. 
0 · Reply
pablo4
pablo4 Oct. 3 at 6:58 PM
$VNDA IBB (large pharma ETF) made a 52 week high today. The XBI (small bio ETF) is nearing its 52 week high. Biotech appears to have now reversed an almost 5 year downtrend now. It could be very strong in weeks and months to come, IMO. Of course, pullbacks....but higher lows and higher highs. JMO
0 · Reply
urallidiots
urallidiots Oct. 3 at 4:20 PM
$VNDA Decent price action after good news. I still don't expect any BO offers (hopefully I'm wrong), but as others noted the FDA overhang is gone and we're throwing less money into the litigation fire. Fingers crossed for positive outcomes on these rereviews.
1 · Reply
HoHoHoHum
HoHoHoHum Oct. 3 at 2:17 PM
$VNDA undervalued gem. Let’s go.
0 · Reply
Trendrebel
Trendrebel Oct. 3 at 2:03 PM
$VNDA Golden cross !
0 · Reply
skyrockets_Inc
skyrockets_Inc Oct. 3 at 2:00 PM
$VNDA FDA overhang was the OVERHANG! Time to move to $7-$8 where she belongs before $24/share buyout
0 · Reply
HFlier
HFlier Oct. 2 at 8:09 PM
$VNDA Well if tomorrow pushes a bit we should break the 43 week TTM squeeze!
0 · Reply
skyrockets_Inc
skyrockets_Inc Oct. 2 at 7:45 PM
$VNDA FDA overhang finally gone after years = buyout offers back on the table
0 · Reply
Texout
Texout Oct. 2 at 7:13 PM
$VNDA Position in Place. Someone else to float the boat.
1 · Reply
OJame
OJame Oct. 2 at 7:12 PM
$VNDA we broke that 5.13
0 · Reply
pablo4
pablo4 Oct. 2 at 6:36 PM
$VNDA delayed reaction to great news, IMO.
0 · Reply
HFlier
HFlier Oct. 2 at 5:15 PM
$VNDA Price will drop to allow the FDA employees to load up.
0 · Reply